🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 05/05/2016 | 81,41 | 84,07 | 80,63 | 84,00 | +4,18% | 4,23% | 1.814.600 |
| 04/05/2016 | 81,98 | 82,91 | 80,31 | 80,63 | -1,86% | 3,17% | 1.907.400 |
| 03/05/2016 | 82,18 | 83,27 | 80,81 | 82,16 | -1,01% | 2,99% | 2.063.400 |
| 02/05/2016 | 84,24 | 84,70 | 80,62 | 83,00 | -1,59% | 4,84% | 2.165.400 |
| 29/04/2016 | 85,90 | 86,23 | 83,40 | 84,34 | -2,78% | 3,29% | 2.888.000 |
| 28/04/2016 | 81,24 | 90,25 | 78,84 | 86,75 | +2,66% | 14,04% | 5.463.300 |
| 27/04/2016 | 83,79 | 85,76 | 81,78 | 84,50 | +0,43% | 4,75% | 2.614.900 |
| 26/04/2016 | 85,80 | 86,02 | 83,29 | 84,14 | -1,77% | 3,18% | 1.689.800 |
| 25/04/2016 | 86,26 | 87,45 | 85,02 | 85,66 | -1,31% | 2,82% | 1.460.100 |
| 22/04/2016 | 86,36 | 87,38 | 84,08 | 86,80 | -0,01% | 3,82% | 1.279.000 |
| 21/04/2016 | 84,39 | 87,49 | 84,10 | 86,81 | +3,21% | 4,02% | 1.731.200 |
| 20/04/2016 | 83,72 | 84,90 | 83,25 | 84,11 | +1,08% | 1,97% | 1.492.300 |
| 19/04/2016 | 84,00 | 84,78 | 82,61 | 83,21 | -0,01% | 2,58% | 1.667.900 |
| 18/04/2016 | 81,42 | 85,90 | 81,42 | 83,22 | +1,80% | 5,50% | 2.495.600 |
| 15/04/2016 | 87,42 | 87,60 | 81,02 | 81,75 | -6,12% | 7,53% | 4.163.700 |
| 14/04/2016 | 85,13 | 88,08 | 84,73 | 87,08 | +2,23% | 3,94% | 1.319.200 |
| 13/04/2016 | 84,04 | 85,64 | 83,20 | 85,18 | +2,17% | 2,90% | 2.128.100 |
| 12/04/2016 | 84,79 | 85,19 | 82,54 | 83,37 | -1,30% | 3,13% | 1.832.700 |
| 11/04/2016 | 85,96 | 86,79 | 84,06 | 84,47 | -0,91% | 3,18% | 1.413.000 |
| 08/04/2016 | 87,29 | 88,00 | 84,18 | 85,25 | -1,22% | 4,38% | 1.539.700 |
| 07/04/2016 | 90,31 | 91,78 | 85,93 | 86,30 | -5,49% | 6,48% | 2.797.600 |
| 06/04/2016 | 83,82 | 91,76 | 83,70 | 91,31 | +8,50% | 9,62% | 3.460.300 |
| 05/04/2016 | 82,54 | 86,48 | 81,52 | 84,16 | +1,56% | 6,01% | 2.849.000 |
| 04/04/2016 | 79,81 | 84,40 | 79,19 | 82,87 | +4,70% | 6,53% | 2.744.000 |
| 01/04/2016 | 79,02 | 79,25 | 75,92 | 79,15 | -0,43% | 4,21% | 3.638.700 |
| 31/03/2016 | 78,72 | 82,10 | 77,81 | 79,49 | +1,39% | 5,45% | 3.259.400 |
| 30/03/2016 | 80,11 | 81,99 | 77,69 | 78,40 | -1,06% | 5,37% | 1.729.500 |
| 29/03/2016 | 78,49 | 79,37 | 76,79 | 79,24 | +0,69% | 3,29% | 1.742.100 |
| 28/03/2016 | 80,85 | 81,26 | 77,67 | 78,70 | -2,33% | 4,44% | 1.508.400 |
| 24/03/2016 | 79,71 | 82,19 | 78,25 | 80,58 | +0,54% | 4,94% | 1.888.300 |